12 Best Biotech Penny Stocks To Invest In Now

2. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Number of Hedge Fund Investors: 30

Stock Price as of December 26: $4.23

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a biopharmaceutical company that leverages computational technology such as the 4D drug design, to develop precision medicines targeting protein motion. This innovative approach has enabled the discovery of therapies for cancers and other diseases. Relay Therapeutics, Inc. (NASDAQ:RLAY) collaborates with biopharmaceutical partners and researchers to accelerate the delivery of transformative treatments. The company’s pipeline includes several clinical and preclinical programs.

Relay Therapeutics, Inc.’s (NASDAQ:RLAY) core technology, the 4D drug Design Platform, stands at the forefront of computational and experimental methods to understand the dynamic movement of proteins. This approach allows the company to design drugs that are more selective and less prone to off-target effects. For instance, Relay Therapeutics, Inc. (NASDAQ:RLAY) is developing Rly-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which has shown promising early results in clinical trials, including an 88% overall response rate (ORR) in the ReFocus trial. This early success has positioned the company to file for FDA approval in treating cholangiocarcinoma with FGFR2 alterations.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is expanding its clinical trials for Rly-4008 and Rly-2608. For Rly-4008, the company is exploring additional indications and has received guidance from the FDA to file for a new drug application (NDA) in cholangiocarcinoma, followed by a tumor-agnostic supplemental application. Additionally, Relay Therapeutics, Inc. (NASDAQ:RLAY) is seeking commercial partnerships to leverage the commercialization of rly-4008.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is also committed to expanding its pipeline through both internal development and strategic collaborations. The company is advancing Rly-2608, a mutant PI3Ka inhibitor, which has shown promising interim data in heavily pretreated patients with PI3Ka-mutations. Relay Therapeutics, Inc. (NASDAQ:RLAY) is also developing additional candidates, including Rly-1156, a selective and Potent inhibitor of the PI3Ka pathway.